IDEXX Laboratories (NASDAQ:IDXX) Updates FY 2026 Earnings Guidance

Key Points

• FY 2026 guidance: company guided to EPS of 14.450–14.900 (vs. consensus 14.520) and revenue of $4.7–$4.8 billion (vs. consensus $4.7B), essentially in line with analyst expectations.
• In Q1 IDEXX reported $3.30 EPS, missing the $3.42 consensus, while revenue was $1.14 billion, slightly above estimates.
• Insider selling and analyst activity: insiders have sold roughly 45,957 shares (~$29.9M) in the last 90 days, several firms trimmed price targets, but the consensus Street target remains $751 with an average rating of "Moderate Buy."

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided EPS guidance of 14.450-14.900 for the period, compared to the consensus EPS estimate of 14.520. The company issued revenue guidance of $4.7 billion-$4.8 billion, compared to the consensus revenue estimate of $4.7 billion.

IDEXX Laboratories Price Performance

Shares of IDEXX Laboratories stock opened at $563.12 on Tuesday. IDEXX Laboratories has a twelve month low of $465.00 and a twelve month high of $769.98. The company has a quick ratio of 0.90, a current ratio of 1.23 and a debt-to-equity ratio of 0.23. The company has a 50-day simple moving average of $589.55 and a two-hundred day simple moving average of $651.34. The stock has a market capitalization of $44.73 billion, a price-to-earnings ratio of 43.08, a price-to-earnings-growth ratio of 3.45 and a beta of 1.58.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $3.30 earnings per share for the quarter, missing the consensus estimate of $3.42 by ($0.12). IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The business had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Analysts forecast that IDEXX Laboratories will post 14.54 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. UBS Group dropped their target price on shares of IDEXX Laboratories from $730.00 to $640.00 and set a "neutral" rating for the company in a research report on Tuesday, April 28th. Citigroup began coverage on shares of IDEXX Laboratories in a research report on Wednesday, April 15th. They issued a "neutral" rating and a $650.00 target price for the company. Barclays lowered their price objective on shares of IDEXX Laboratories from $850.00 to $800.00 and set an "overweight" rating for the company in a research report on Thursday, February 5th. BTIG Research lowered their price objective on shares of IDEXX Laboratories from $830.00 to $800.00 and set a "buy" rating for the company in a research report on Tuesday, February 3rd. Finally, Weiss Ratings reiterated a "hold (c+)" rating on shares of IDEXX Laboratories in a research report on Monday, April 27th. Seven analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $751.00.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, EVP George Fennell sold 11,345 shares of the company's stock in a transaction that occurred on Tuesday, February 10th. The shares were sold at an average price of $646.72, for a total value of $7,337,038.40. Following the completion of the transaction, the executive vice president directly owned 9,823 shares in the company, valued at approximately $6,352,730.56. This represents a 53.60% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Jonathan Jay Mazelsky sold 23,326 shares of the company's stock in a transaction that occurred on Thursday, February 26th. The shares were sold at an average price of $657.55, for a total transaction of $15,338,011.30. Following the completion of the transaction, the chief executive officer owned 83,606 shares of the company's stock, valued at approximately $54,975,125.30. This trade represents a 21.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 45,957 shares of company stock worth $29,862,109. 0.79% of the stock is currently owned by insiders.

Institutional Investors Weigh In On IDEXX Laboratories

A number of institutional investors have recently modified their holdings of IDXX. Virtus Advisers LLC bought a new stake in shares of IDEXX Laboratories in the 3rd quarter valued at $26,000. WealthCollab LLC bought a new stake in shares of IDEXX Laboratories in the 2nd quarter valued at $30,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of IDEXX Laboratories in the 3rd quarter valued at $36,000. Johnson Financial Group Inc. boosted its stake in shares of IDEXX Laboratories by 1,475.0% in the 3rd quarter. Johnson Financial Group Inc. now owns 63 shares of the company's stock valued at $40,000 after purchasing an additional 59 shares during the last quarter. Finally, Kemnay Advisory Services Inc. bought a new stake in shares of IDEXX Laboratories in the 4th quarter valued at $54,000. 87.84% of the stock is owned by institutional investors.

About IDEXX Laboratories

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.